miR-92a family and their target genes in tumorigenesis and metastasis  by Li, Molin et al.
Available online at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/yexcr
E X P E R I M E N T A L C E L L R E S E A R C H 3 2 3 ( 2 0 1 4 ) 1 – 60014-4827 & 2013 Th
http://dx.doi.org/10.1
nCorresponding au
nnCorresponding a
E-mail addressesReview ArticlemiR-92a family and their target genes in
tumorigenesis and metastasisMolin Lia,b,n, Xingfang Guana, Yuqiang Suna, Jun Mib, Xiaohong Shuc, Fang Liud,
Chuangang Lid,nn
aDepartment of Pathophysiology, Basic Medical Science of Dalian Medical University, Dalian 116044, China
bInstitute of Cancer Stem Cell, Dalian Medical University Cancer Center, Dalian 116044, China
cCollege of Pharmacy, Dalian Medical University Cancer Center, Dalian 116044, China
dDepartment of Surgery, The Second Afﬁliated Hospital of Dalian Medical University, Dalian 116027, Chinaa r t i c l e i n f o r m a t i o n
Article Chronology:
Received 19 November 2013
Accepted 18 December 2013
Available online 4 January 2014
Keywords:
miR-92a family
Target genes
Regulation
Tumorse Authors. Published by E
016/j.yexcr.2013.12.025
thor at: Department of Pa
uthor.
: molin_li@hotmail.com (Ma b s t r a c t
The miR-92a family, including miR-25, miR-92a-1, miR-92a-2 and miR-363, arises from three
different paralog clusters miR-17-92, miR-106a-363, and miR-106b-25 that are highly conserva-
tive in the process of evolution, and it was thought as a group of microRNAs (miRNAs) correlated
with endothelial cells. Aberrant expression of miR-92a family was detected in multiple cancers,
and the disturbance of miR-92a family was related with tumorigenesis and tumor development.
In this review, the progress on the relationship between miR-92a family and their target genes
and malignant tumors will be summarized.
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MicroRNAs (miRNAs) are a class of single-stranded small mole-
cule RNA with around 22 nucleotides in length. The miR-17-92
cluster, the ﬁrst discovered oncogene [1], was grouped into four
different families based on their seed sequence homology:
namely, miR-17 family, mir-18 family, miR-19 family, and miR-
92 family. It is known that the miR-92a family is related to the
formation of vascular endothelial cells [2–4]. Aberrant expression
of miR-92a family was detected in multiple cancers, and the
disturbance of miR-92a family was related with tumorigenesis
and tumor development. The miR-92a family may have potential
value as tumor markers or new targets for cancer treatment. In
this review, the progress on the miR-92a family and their target
genes in malignant tumors will be summarized.The miR-92a family
The miR-92a family is a group of highly conserved miRNAs
including miR-25, miR-92a-1, miR-92a-2 and miR-363, which
has identical seed region and arises from three different paralog
clusters miR-17-92, miR-106a-363, and miR-106b-25 [5]. Recent
studies found that miR-25 was located in the 13th intron of the
minichromosome maintenance protein 7 (MCM7) gene of human
chromosome 7q22.1 or located on mouse ﬁfth X chromosome [6].
MiR-92a-1 is situated within the third intron of an open reading
frame 25 (C13orf25) gene located at chromosome 13q31-q32 [7].
Both miR-25 and miR-92a-1 belong to intronic miRNAs. Both miR-
92a-2 and miR-363 are encoded in miR-106-363 cluster on the X
chromosome, region q26.2, and Kis2 ncRNAs are their pri-miRNAs
[8]. Both miR-92a-1 and miR-92a-2 could be processed to gen-
erate mature miRNA-92a.
MiR-92a family plays an important role in regulating not only
the development of mammalian organs including heart, lungs and
immune system but also the formation of blood vessels. Ventura
etc [9] reported that mice deﬁcient for miR-17-92 cluster die
shortly after birth with lung hypoplasia and a ventricular septal
defect. Suarez et al. [10] showed that deletion of Dicer would
reduce the postnatal angiogenic response of mice to a variety of
stimuli, including exogenous VEGF, tumors, limb ischemia, and
wound healing. Transfection of endothelial cells with miR-17-92
cluster at the time of VEGF stimulation could partially rescue
endothelial cell proliferation and morphogenesis initiated by the
loss of Dicer. Besides, it was also reported that miR-92a family
members were associated with the proliferation and differentia-
tion of lung progenitor cells, and with the differentiation of
preadipocyte and human trophoblast as well [11–13].The expression of miR-92a family in malignant
tumors
Volinia etc [14] measured the expression of miRNAs in 540 tumor
samples including lung, breast, stomach, prostate, colon, and
pancreatic tumors, and identiﬁed that miR-92a was markedly
overexpressed in tumor tissues from a large-scale miRnome
analysis. It was also reported that the up-regulation of miR-92ain colorectal cancer was correlated with the status of lymph
node metastasis and prognosis [15]. The expression of miR-92a
was up-regulated in the tissues of clear cell renal cell carcinoma
(ccRCC). The overexpression of miR-92a was directly related with
tumor differentiation, but inversely correlated with VHL mRNA
levels [16]. Ranade et al. [17] demonstrated that miR-92a-2 was
increased in the tumor tissues of small cell lung cancer (SCLC),
and it could be served as a biomarker predictive for chemoresis-
tance and prognostic for survival in SCLC patients. However, it
was also reported that the expression of miR-92a was increased in
the tissues of HCC, multiple myeloma, and NHL; while its
expression was obviously lower in plasma of patients compared
with healthy subjects [18–20]. The level of miR-92a was signiﬁ-
cantly lower in both tumor tissues and serum samples of breast
cancer patients than in that of healthy controls, and the levels of
miR-92a was found to be related with tumor size and lymph node
metastasis [21,22]. Besides, miR-92a was signiﬁcantly higher in
both acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL) cells than in PBMNC from healthy volunteers.
It was preferentially expressed in ALL cells in comparison with
AML cells, and ALL patients with overexpressed miR-92a had poor
prognoses [23].
It was observed that the expression of miR-25 was highly
expressed in a variety of tumor tissues including gastric, ovarian,
prostate, esophageal and colorectal cancer tissues than in normal
control tissues, and the overexpression of miR-25 was negatively
associated with TNM stage in esophageal cancer [24–28]. It was
also reported that miR-363 was down-regulated in tissues of head
and neck squamous cell carcinoma (HNSCC) [29].The regulation of miR-92a family
The regulation of miR-92a family member expression occurs in
different levels: (1) The chromosome level: It is known that the
tumor genesis was commonly accompanied with abnormalities of
chromosomes including deletion, ampliﬁcation, or translocation of
chromosomes. Loss of heterozygosity (LOH) or ampliﬁcation of miR-
92a family members could lead to the alteration in microRNA locus
copy number. Ota et al. [7] reported for the ﬁrst time that the
ampliﬁcation at 13q31–q32 existed in diffuse large B-cell lymphoma,
accompanied by the increased expression of Chromosome 13 open
reading frame 25 (C13orf25) and miR-92a. Zhang et al. [30]
demonstrated that the heterozygous deletion of 13q31.3 was
detected in the tissues of ovarian cancers, breast cancers, and
melanomas, resulting in the decreased expression of miR-92a gene.
Liu et al. [31] reported that there was a single nucleotide poly-
morphism (SNP), rs999885, in the promoter region of miR-106b-25
cluster, and therefore inﬂuence the expression of miR-25. Besides
these, Sevignani et al. [32] reported that MicroRNA genes are
frequently located near cancer susceptibility loci. Makunin et al.
[33] found that 10 cancer-associated regions (Common Integration
Sites, CIS)-associated miRNA loci containing 22 miRNAs was located
within 10 kb of known CIS insertions, and they thought that the
expression of miRNA was associated with clustered inserts from CIS.
(2) Methylation regulation: MiRNA genes might be silenced by
aberrant hypermethylation of CpG islands that encompass or lie
adjacent to miRNA genes, and Kunej et al. [34] found the expression
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Transcription level: Combining with the promoters of miR-17-92
[35], miR-106a-363 and miR-106b-25 cluster, several transcription
factors regulated the expression of miR-92a family members. Ming
et al. [36] demonstrated transcription factor SP1 and MYC could
combine with the promoter of miR-17-92 cluster and induce a
transcriptional activation. Further, they found that the promoter
activity was decreased after the mutation of putative SP1-binding
sites; while the promoter activity was enhanced after the mutation
of putative MYC-binding sites. E2F is a group of genes that codiﬁes a
family of transcription factors (TF) which play a crucial role in
controlling the cell cycle and apoptosis [37]. It was reported that E2F
family members could directly induce the transcription of miR-
106b-25 cluster and miR-17-92 cluster [38–40]. Up-regulation of
MYC could not only activate the transcription of E2F but also induce
the expression of a variety of microRNAs including miR-17-92
cluster, miR-106a-363 cluster and miR-106b-25 cluster [41–44].
Moreover, other transcription factors such as wild-type p53, signal
transducer and activator of transcription-3 (STAT3), Cyclin D1 etc
could directly induce the transcription of miR-17-92 cluster [39,45–
47], and transcription factor homeoprotein Sine oculis homeobox
homolog 1 (Six1) could also up-regulate the expression of mir-106b-
25 cluster [48].Functions and mechanism of miR-92a family in
tumorigenesis and development
Promoting tumor proliferation
It is well known that PI3K/Akt/mTOR pathway is an intracellular
signalling pathway important in apoptosis and longevity. It is
closely related with tumorigenesis and development. Rao et al.
[49] demonstrated that miR-92a could directly target protein
phosphatase PH domain leucine-rich repeat protein phosphatase
(PHLPP2), an important negative regulator of the PI3K/Akt/mTOR
pathway. Upregulation of miR-92a could activate the PI3K/Akt/
mTOR pathway, and inhibit cell apoptosis induced by chemother-
apy in mantle cell lymphoma (MCL) cells; while down regulation
of miR-92a could inhibit the growth of tumors in a xenograft MCL
mouse model. The Von Hippel–Lindau tumor suppressor also
known as pVHL is a protein that is encoded by the VHL gene.
pVHL causes the polyubiquitylation of HIF-1α, ensuring that this
protein will be degraded and the expression of the target genes of
HIF-1αwill be inhibited. Ghosh AK and colleagues [50] found that
miR-92a-1 could directly target VHL gene, stabilize the expression
of HIF-1α, and then HIF-1α combines with transcriptional coacti-
vator p300 and phosphorylated-STAT3 to form an active complex
that directly promotes the transcription of VEGF as a transcription
factor. p57Kip2 is a Cip/Kip family member of cyclin-dependent
kinase(CDK) inhibitors. It could inhibit several G1 cyclin/Cdk
complexes resulting in cell-cycle arrest. Kim et al. [51] demon-
strated that miR-25 could directly inhibit the expression of P57.
Ectopic expression of miR-25 could activate Cdk2 and facilitate
G1/S phase transition, and promote cell proliferation. Shigoka
et al. [18] validated that miR-92a could promote the proliferation
of HCC; while antagonist of miR-92a (antagomir) could inhibit the
proliferation of HCC.Inhibiting tumor apoptosis
Bim (Bcl-2 interacting mediator of cell death) is one of the most
important pro-apoptotic factors that belong to the BH3-only
group of Bcl-2 family members, which is extensively expressed
in normal tissues. The activated Bim could induce the activation of
Bax through direct interaction with Bcl-2/Bax complexes, thus
giving rise to mitochondrial pathway of apoptosis. It was reported
that miR-92a and miR-25 could target Bim directly, and play
important roles in inhibiting tumor cell apoptosis and promoting
tumorigenesis. Niu et al. [52] found that the expression of miR-
92a was increased in human glioma specimens, and it was
adversely related to levels of BCL2L11 (Bim) protein, and corre-
lated with the degree of malignant tumors. Further, they demon-
strated that miR-92a could directly target Bim, and by using
antisense oligonucleotide (AS-miR-92a) they showed that miR-
92a inhibitor could signiﬁcantly increase the incidence of apop-
tosis in tumor cells. These results indicated that miR-92a had a
protumorigenic effect. Tsuchida et al. [53] demonstrated that the
expression of miR-92a was increased in colon adenomas and
carcinoma, and it could target Bim directly and inhibit colon
carcinoma cell apoptosis; while miR-92a inhibitor could induce
colon carcinoma cell apoptosis. MiR-25 could also target Bim
directly, and it played a pivotal role in regulating tumor cell
apoptosis [25,54].
P53, an important tumor suppressor protein, is encoded by the
TP53 gene in human. It is thought that wild-type (wt) P53 plays a
key role in participating in the control of the cell cycle check-
points, activating DNA repair or inducing cellular apoptosis; while
mutant P53 not only loses the tumor suppressor functions of
wild-type p53 but also acquire additional tumorigenetic roles.
Kumar et al. [55] demonstrated that miR-25 could directly target
the p53 gene and inhibit the expression of p53-dependent genes.
MiR-25 could inhibit cell apoptosis, cell cycle arrest and cell
senescence; correspondingly, inhibition of miR-25 expression
could increase the expression of endogenous p53, leading to
tumor cell apoptosis in several tumors. It is commonly known
that murine double minute 2 (Mdm2) and tuberous sclerosis
comlex type1 (TSC1) are negative regulators of p53 and mTOR
pathways in cells. Suh et al. [56] discovered that miR-25 could
target Mdm2 and TSC1 directly. They thought that the reduction
of Mdm2 could not induce p53 ubiquitination, and cause the
accumulation of wild-type p53 protein, leading to growth arrest
in glioblastoma cells and inhibition of cell proliferation.
Death receptor 4(DR4), a member of the tumor necrosis factor
receptor (TNFR) family, is a receptor for the cytotoxic ligand TRAIL
(Apo2 ligand). It also contains a cytoplasmic death domain, and
oligomerization of the death domain would recruit caspase 8 and
activate the subsequent cascade of caspase proteases, resulting in
apoptosis. Razumilava et al. [57] demonstrated that miR-25 could
target DR4 directly, and protected cells against TNF-related
apoptosis-inducing factors-induced apoptosis. Antagonism of
miR-25 could increase the sensitivity of cells to apoptotic death.
Promoting tumor invasion and metastasis
Epithelial to mesenchymal transition (EMT) refers to the progres-
sion in which tumor epithelial cells acquire mesenchymal features
with high abilities of invasiveness and metastasis under various
factors. It is a highly complex process, and is regulated by
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and E-cadherin etc. Among them, TGF-β signaling pathway was
generally thought to be the main mechanism that drove and
promoted EMT. Binding to cell surface receptors, TGF-β activated
or inhibited the transcription of genes through TGF-β/Smads
signaling pathway so that inhibited cell proliferation, induced
cell differentiation and apoptosis. It played a crucial role in
tumorigenesis and metastasis in some tumors such as breast
carcinoma, pancreatic carcinoma, colon and ovarian cancers etc.
It is accepted that TGF-β has suppressive effects on the early stage
of carcinogenesis or on the normal epithelial cells. As cancer
progresses, tumor cells become resistant to TGF-β mediated
growth inhibition, and TGF-β promotes tumor invasion and
metastasis partly through its promotion of the transformation of
EMT, and it might be associated with miR-106b-25 cluster. It was
reported that miR-25 could target cell cycle inhibitor p21 and the
pro-apoptotic factor Bim in TGF-β signal pathway, and inhibit
TGF-β mediated tumor cell growth suppression [40,54]. And it
was also showed that miR-106b-25 cluster could also target the
inhibitory Smad7 directly, resulting in the increased levels of the
TGF-β type I receptor and downstream activation of TGF-β
signaling [24,48].
Integrins are divalent cation-dependent molecules and belong
to a family of heterodimeric transmembrane receptors. They
mainly mediate cell–cell and cell–extracellular matrix interactions
and facilitate growth and metastasis [58]. Ohyagi-Hara et al. [59]
demonstrated that miR-92a could directly target integrin α5
(ITGA5). Transfection of precursor miR-92a would reduce integrin
α5 expression in ovarian cancer cells, accompanied by the
inhibition of cancer cell adhesion, invasion, and proliferation.
The enforced expression of miR-92a would suppress peritoneal
dissemination of ovarian cancer in vivo. E-cadherin (E-cad, CDH1)
is a classical member of the cadherin superfamily. The encoded
protein is a calcium-dependent cell–cell adhesion glycoprotein
that could inhibit tumor metastasis by promoting recognition and
adhesion of tumor cells. It was reported that both miR-92a and
miR-25 could directly target CDH1 gene, which were closely
correlated with the lymphatic metastasis and invasion of esopha-
geal squamous cell carcinoma [60–61]. Desmocollin2 (DSC2), a
member of the desmocollin subfamily of the cadherin super-
family, is involved in cell–cell adhesion and plays a critical role in
maintaining normal tissue architectures in the epithelium. Fang
et al. [27] demonstrated that miR-25 could target DSC2 gene
directly at post-transcription level. Down-regulated DSC2 would
promote esophageal squamous cell carcinoma cells aggressive-
ness through redistributing adherens junctions and inducing the
transposition of β-catenin from cytoplasm to the nuclear, and
further activate the transcription of β-catenin/TCF.Conclusions
Numerous studies have shown that the elevated expression of
microRNA miR-92a and/or miR-25could be detected in many
different types of tumor tissues, and the dysregulated miR-92a
family members are associated with tumor stage or size, tumor
metastasis and prognosis. Due to the fact that miRNAs exist stably
in tumor tissues and circulating blood, miR-92a family members
might be served as predictive biomarkers associated with tumordiagnosis or chemoresistance and prognostic for survival in some
patients with tumors.
A variety of experiments have demonstrated the contributing
effect of miR-92a on tumorigenesis. The underlying mechanisms
mainly include promoting tumor proliferation, inhibiting tumor
apoptosis, and promoting tumor invasion and metastasis. There-
fore, miR-92a might be a target for cancer therapy in future.
Understanding the biological function of miR-92a family mem-
bers is perhaps the biggest challenge facing the ﬁeld of tumor
stem cells and tumor multidrug resistance at the moment. As a
result, there is an urgent need to gain further insights into the
mechanisms of the miR-92a family members and their target
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